

Max Healthcare Institute Limited
Disclosure of Related Party Transactions for the half year ended September 30, 2025 pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

(Figure in INR Lakhs)

S. No	Details of the Party (Listed entity / subsidiary) entering into the transaction		Details of the Counterparty		Type of Related Party Transaction	Value of the Related Party Transaction as approved by the Audit Committee (Refer note - b)	Value of the related party transaction ratified by the Audit Committee	Value of transaction during the reporting period (i.e. April 1, 2025 till September 30, 2025)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Security deposit received as per Company's car policy for employees					Refer Note (k) below	-	-	Opening balance	Closing balance	Details of the loans, inter-corporate deposits, advances or investments						
														Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (Loan/ Advance/ Inter-Corporate Deposit/ Investment)	Interest Rate (%)	Tenure	Secured/ Unsecured
258	Max Lab Limited	Mr. Swarnil Soni	Key Managerial Personnel of subsidiary	Security deposit received as per Company's car policy for employees	Refer Note (k) below	-	-	4.00	4.00	NA.	NA.	NA.	NA.	NA.	NA.	NA.	NA.			
259	Max Lab Limited	Mr. Arpan Malhotra	Director of subsidiary	Security deposit received as per Company's car policy for employees	Refer Note (k) below	-	-	10.00	10.00	NA.	NA.	NA.	NA.	NA.	NA.	NA.	NA.			
260	Starit Medical centre Private Limited	Mr. Pramit Mishra	Director of subsidiary	Security deposit received as per Company's car policy for employees	Refer Note (k) below	-	-	3.00	3.00	NA.	NA.	NA.	NA.	NA.	NA.	NA.	NA.			

NOTES:

- a) The above transactions with related parties are excluding of taxes and are made on terms equivalent to those that prevail in arm's length transactions.
- b) The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors of the Company, as applicable, for financial year 2025-26.
- c) As the future liability for gratuity and compensated absences is provided on an actuarial basis for the Company as a whole, the amount pertaining to the directors has not been ascertained separately and, therefore, not included in above mentioned managerial remuneration. Managerial remuneration mentioned above also do not include accrual recorded towards employee share based payments but includes benefits value on account of ESOP exercise during the reporting period.
- d) As per approval given by Nomination & Remuneration Committee/Board of Directors/Shareholders, as may be applicable.
- e) All the above number are rounded off to lakhs unless otherwise specified.
- f) Investment and loan given (including interest due thereon) to subsidiary 'MHC Global Healthcare (Nigeria) Ltd' has been provided for in the books of accounts on account.
- g) Foreign subsidiary and minors does not have PAN.
- h) Remuneration and sitting fees paid by the listed entity or its subsidiary to its director, key managerial personnel or senior management, except who is part of promoter or promoter group, shall not require approval of the audit committee provided that the same is not material in terms of the provisions of regulation 23 (i) of SEBI LODR.
- i) Actualization of provision resulted in written back of provision
- j) Entity where company has contractual arrangements ('silo' or 'deemed subsidiary')
- k) As per company HR policy
- l) Pine Labs Limited (PL) was related party till June 6, 2025 only in current period when it was a private company through common director. After its conversion into public company and the common director does not hold any shares more than 2%, it does not qualify to be a related party of the Company w.e.f June 06, 2025. Amount under Omnibus Approval for FY 2025-26.